Join MyFreeStyle and get your first sensor for FREE* Find out more.

  

|

Proven results in Type 2 diabetes - Now you know

Proven results in Type 2 diabetes - Now you know

FreeStyle Libre is clinically proven to reduce HbA1c in people living with type 2 diabetes (T2D)18,21,27,28

Non-insulin therapy

 A1c inside a circle next to a wide blue downwards arrow showing a decrease of 1.6 percent.

After 22 weeks

In people with T2D who were using non-insulin therapy and FreeStyle Libre (p<0.001 vs. baseline A1c)27

Basal insulin users

A1c inside a circle next to a wide blue downwards arrow showing a decrease of 1.1 percent.

After 22 weeks

In people with T2D who were using basal insulin and FreeStyle Libre (p<0.001 vs. baseline A1c)27

A downward pointing yellow arrow.

Baseline A1c:

10.1%

Follow-up A1c:

8.5%

Lowering HbA1c reduces your risk of diabetes related complications

 

Non-insulin therapy

A1c inside a circle next to a wide blue downwards arrow showing a decrease of 0.9 percent.

At 24 weeks

In people with T2D who were using non-insulin therapy and FreeStyle Libre system (p<0.0001)21

Patients with T2D on MDI

A1c inside a circle next to a wide blue downwards arrow showing a decrease of 0.82 percent.

In 10 weeks

In people with T2D on MDI using the FreeStyle Libre system saw a significant A1c reduction compared to SMBG (0.82% vs 0.33%, respectively, p=0.005)28

 

In patients with T2D, oral medications have shown to reduce A1c by 0.60% to 1.12%18

Abbreviations: A1: glycated haemoglobin; MDI: multiple daily injections; SMBG: self-monitoring of blood glucose; T2D: type 2 diabetes.

References: 18. Hirst JA, et al. Diabetes Care. 2012;35(2):446–454. 21. Miller E, Brandner L, Wright E. HbA1c reduction after initiation of the FreeStyle Libre system in type 2 diabetes patients on long-acting insulin or non-insulin therapy [84-LB]. Poster presented at: 80th Scientific Sessions of the American Diabetes Association; June 12-16, 2020;Virtual. 27. Wright E, et al. Diabetes Spectrum. 2021;34(2):184–189. 28. Yaron, M. Diabetes Care 2019;42(7):1178–1184.